CochLear (OTCMKTS:CHEOY – Get Free Report) and SeaStar Medical (NASDAQ:ICU – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Risk & Volatility
CochLear has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.05, indicating that its share price is 205% less volatile than the S&P 500.
Insider and Institutional Ownership
1.7% of SeaStar Medical shares are owned by institutional investors. 0.7% of SeaStar Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CochLear | $1.53 billion | 3.35 | $251.85 million | N/A | N/A |
| SeaStar Medical | $1.23 million | 12.65 | -$12.15 million | ($4.80) | -0.81 |
CochLear has higher revenue and earnings than SeaStar Medical.
Analyst Ratings
This is a summary of current recommendations and price targets for CochLear and SeaStar Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CochLear | 0 | 5 | 0 | 1 | 2.33 |
| SeaStar Medical | 1 | 0 | 1 | 0 | 2.00 |
CochLear presently has a consensus target price of $117.00, suggesting a potential upside of 199.77%. SeaStar Medical has a consensus target price of $8.00, suggesting a potential upside of 105.66%. Given CochLear’s stronger consensus rating and higher possible upside, equities research analysts clearly believe CochLear is more favorable than SeaStar Medical.
Profitability
This table compares CochLear and SeaStar Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CochLear | N/A | N/A | N/A |
| SeaStar Medical | -828.62% | -146.29% | -96.48% |
Summary
CochLear beats SeaStar Medical on 9 of the 13 factors compared between the two stocks.
About CochLear
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
About SeaStar Medical
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.
